CCTV Tianjin, January 11 (Reporter Chu Fuqing) Recently, the 4th China Hematology Development Conference was successfully held in Tianjin. Focusing on "big blood, big health, and big health", the conference focused on the key construction and core development direction of China's hematology in the new era, carried out all-round, multi-dimensional and in-depth exchanges and exhibitions on the frontier hot spots in the field, and released the major information in the field of hematology in 2023 and the results of the top ten research progress in hematology in 2023.
The scene of the conference (courtesy of the Central Broadcasting Network).
Since the first conference on the development of hematology in 2021, this conference was held offline for the first time. The three-day conference was broadcast live on 28 platforms, and the total number of hematology colleagues and the public at home and abroad exceeded 7 million, setting off an upsurge of learning, attention and discussion in the field of hematology at the beginning of the year.
The conference comprehensively reviewed and released important information in the field of hematology in 2023 from the aspects of "Important Monographs", "Guidelines and Consensus", "National Platform", "Made in China" and "Collaborative Innovation". At the main forum on January 7, the top ten research advances in hematology in China in 2023 were released, and the recommended scientific progress was all the research results published between January 1, 2023 and December 31, 2023 and the core scientific discoveries completed in China. The "Top Ten Research Advances in Hematology in China in 2023" include the use of monkey embryo in vitro culture technology to analyze the origin of early hematopoiesis in monkeys, identify and target leukemia stem cells for acute T lymphoblastic leukemia, a new and precise protocol for diffuse large B-cell lymphoma based on molecular typing, solve the mystery of anemia and thrombocytosis in cancer patients, and analyze the hematopoietic regeneration law of allogeneic hematopoietic stem cell transplant patients with single-cell analysis.
The conference closely followed the international hotspots and based on practical needs, and carried out 21 thematic forums, 4 online thematic forums, 3 closed-door meetings and 1 special meeting in parallel. Professor Cheng Tao, Chairman of the Conference and Director of the Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences (School of Basic Medical Sciences, Peking Union Medical College), made a summary of the conference.
Cheng Tao said that the conference focused on the core development direction of hematology, as well as the major disciplinary issues faced in the basic research, transformation and clinical diagnosis and treatment of hematology in the new era, and carried out hot and cutting-edge sharing and in-depth sharing, covering all aspects from basic research, clinical diagnosis and treatment to popular science guidance, realizing the improvement of the scale of the conference, the content of activities, academic exchange, cooperation and sharing, etc., and achieved fruitful results and extensive social influence. 2024 is a year of both opportunities and challenges, he emphasized that the institute will continue to benchmark against the world's top medical research institutions, give full play to the advantages of the vanguard of hematological diseases and the national team, and work with colleagues in the field to focus on the needs of discipline development and key issues, strengthen basic research, carry out standardized clinical research, and promote the transformation of scientific and technological achievements, strengthen the planning and layout of hematology in China, and jointly draw a grand blueprint for the construction and development of hematology in China.
*: CNR).
For more exciting information, please contact the application market**"Jimu News" client, do not be authorized**, welcome to provide news clues, and pay once adopted.